NNM Securities

COMPANY
more from company profile
HomeMarket Info Company Profile Smart Quotes

Smart Quotes

LUPIN LTD.

NSE : LUPINBSE : 500257ISIN CODE : INE326A01037Industry : Pharmaceuticals & DrugsHouse : Lupin
BSE1615.8526.75 (+1.68 %)
PREV CLOSE ( ) 1589.10
OPEN PRICE ( ) 1585.60
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 42605
TODAY'S LOW / HIGH ( )1585.60 1623.90
52 WK LOW / HIGH ( )680.35 1703.8
NSE1615.9521.55 (+1.35 %)
PREV CLOSE( ) 1594.40
OPEN PRICE ( ) 1590.00
BID PRICE (QTY) 1615.95 (468)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 587789
TODAY'S LOW / HIGH( ) 1585.10 1624.00
52 WK LOW / HIGH ( )680 1704.25
BSE
1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Incorporation Year : 01-03 1983
Management Info
Manju D Gupta - Chairman Nilesh Gupta - Managing Director
Registered Office

Address Kalpataru Inspire, 3rd Floor,Off. Western Express Highway,Santacruz (East),
Mumbai,
Maharashtra-400055

Phone 022 66402323

Email info@lupin.com

Website www.lupin.com

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, MCX
NEWS
24Apr Lupin gets EIR for Aurangabad manufact
Lupin has received the Establishment Inspection Report (EIR) from the Un..
24Apr Lupin rises on the BSE
Lupin is currently trading at Rs. 1595.15, up by 14.60 points or 0.92% f..
22Apr Lupin launches Mirabegron Extended-Rel
Lupin has launched Mirabegron Extended-Release Tablets, 25 mg, in the Un..
22Apr Lupin jumps on launching Mirabegron Ex
Lupin is currently trading at Rs. 1594.85, up by 47.80 points or 3.09% f..
22Apr Lupin informs about board meeting
Pursuant to Regulation 29(1)(a) of SEBI (Listing Obligation and Disclosu..
MORE
Financials
Rs. in Millions
QTR Dec 23 ANNUAL 23
Net Profit9164.399999999994252.10000000001
Gross Profit 10839.6 5271.40000000001
Operating Profit 1240511739.2
Net Sales 41157.5112588.3
MORE
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group
Divi's Lab (BSE)
 4025.35 (4.81%)
M.Cap (Rs. in Cr)106860.39
Sanofi India (BSE)
 8278.10 (1.76%)
M.Cap (Rs. in Cr)19064.98
Abbott India (BSE)
 25864.85 (0.54%)
M.Cap (Rs. in Cr)54961.00
Astrazeneca Pharma I (BSE)
 5415.40 (2.18%)
M.Cap (Rs. in Cr)13538.50
Glaxosmithkline Phar (BSE)
 2132.75 (3.26%)
M.Cap (Rs. in Cr)36130.07
MORE
Shareholding Pattern
PROMOTERS 47.01%
MUTUAL FUNDS/UTI 16.82%
FI/BANKS/INSURANCE 10.02%
NON-INSTITUTION 6.93%
GOVERNMENT 0.01%
FII 0%
MORE
Mf Holdings
MORE
ATTENTION INVESTORSKYCIPO
TERMS & CONDITIONS| PRIVACY POLICY| REFUND & CANCELLATION POLICY| DISCLAIMER| DISCLOSURE| KMP DETAILS | CDSL e-Voting | SEBI| FMC| NSE| BSE| MCX | SCORES
Download Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do’s & Don’t’s) in Vernacular Language :
Assamese Bengali Gujrati Hindi Kanada
Kashmiri Konkani Malyalam Marathi Oriya
Punjabi Sindhi Tamil Telegu Urdu
REGISTRATION NOS.

NSE CM-INZ000234235|NSE F& O - INZ000234235, NSE CD-INZ000234235, BSE CM–INZ000234235 |BSE F & O - INZ000234235|BSE CD- INZ000234235 MCX-SX CM-INZ000234235|MCX-SX F & O - INZ000234235|MCX-SX CD-INZ000234235 NSDL - IN-DP-NSDL-319-2009ROC REG - 21-097912,CDSL : IN-DP-242-2016|SEBI-PMS: INP000007100|LEI- 3358007DLCFNHY8J2F96

Filing compliant on SCORES – Easy & quick

  • Register on SCORES portal
  • Mandatory details for filing complaints on SCORES:
    • Name
    • PAN
    • Address
    • Mobile Number
    • E-mail ID
  • Benefits:
    • i.) Effective communication
    • ii.) Speedy redressal of the grievances
SMART ODR Portal
INVESTOR PROTECTION

Compliance officer : Apurva Mittal, Tel No: 022-40790035,022-40790024, Mobile No: 9152943075, E-mail ID: compliance@nnmsecurities.com, cdsl@nnmsecurities.com

Investor grievance : support@nnmsecurities.com

"NNM Securities has partnered with TradingView for its charting technology. An investment and trading platform empowering users with global market data and analytical tools like Stock Screener and Economic Calendar."

Copyright © 2021 NNM Securities.com

Advanced Charts Technology Partner: TradingView

Designed , Developed & Content Powered by ●●● Accord Fintech Pvt. Ltd.